JIA Registry - Abatacept

Trial

Clinical Trial Title

JIA Registry - Abatacept

Trial Status

Open to Enrollment

Start Date

March 15, 2013

Trial Type

Pediatric Rheumatology

Specific Condition

Juvenile Idiopathic Arthritis (JIA)

Description

The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) in routine clinical practice, with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.

Eligibility Criteria

Ages Eligible for Study:  up to 17

Genders Eligible for Study:  Both

Inclusion Criteria:

  • Diagnosis of JIA (any subtype).
  • Age < 18 years at the time of enrollment.
  • Receiving Abatacept at the time of enrollment as per treating physician's decision.
  • Parent or legally acceptable representative willing to participate in the study and sign the informed consent.

IRB Number

10608

Principal Investigator Name

Daniel Kingsbury, MD

Contact Name

Kristin Hickey

Phone

503-413-5447

Contact E-Mail

khichey@lhs.org

Last Updated: Wednesday, September 18, 2013 01:27:45 PM

We'd like to make your experience better.
x

Help us improve our site and be entered to win a $100 gift card.

Take the Survey